Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group.
about
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trialEvidence for different subgroups of difficult asthma in childrenElectronic Noses for Well-Being: Breath Analysis and Energy ExpenditureFeatures of severe asthma in school-age children: Atopy and increased exhaled nitric oxide.Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection.Exhaled nitric oxide in diagnosis and management of respiratory diseases.Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic?Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.Role of exhaled nitric oxide in asthma.Children with difficult asthma: a practical approach.Exhaled markers of pulmonary disease.Severe asthma: definition and mechanisms.Biomarkers of some pulmonary diseases in exhaled breath.Multiple roles of nitric oxide in the airways.Failure of sputum eosinophilia after eotaxin inhalation in asthma.Assessment of airway inflammation with exhaled NO measurement.Current concepts of severe asthmaPartitioned exhaled nitric oxide to non-invasively assess asthma.Effect of fluticasone 250 microg/salmeterol 50 microg and montelukast on exhaled nitric oxide in asthmatic patients.Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications.Severe asthma: from characteristics to phenotypes to endotypes.The investigation of severe asthma to define phenotypes.Clinical application of exhaled nitric oxide measurement in pediatric lung diseases.Neutrophilic Inflammation in Asthma and Association with Disease Severity.Subjects in a Population Study with High Levels of FENO Have Associated Eosinophil Airway Inflammation.A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr.Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases.Exhaled nitric oxide and bronchial wall thickening in asthmatics during and after acute exacerbation: evidence of bronchial wall remodeling.Validation study of fractional exhaled nitric oxide measurements using a handheld monitoring device.Exhaled nitric oxide in healthy children: variability and a lack of correlation with atopy.
P2860
Q24655820-FB6F589E-66F8-4BA0-8FFE-7611644E0CE6Q28363315-31B4F560-6746-4F4E-B1EC-4219DD852390Q28828188-7C12274D-8DA8-4958-A373-8D9DC9A7112BQ30436056-E9BA5250-502D-4FC4-BE5F-A7D4C990BFACQ33379254-3512B4BA-BA16-4737-8115-0A00D17BF35AQ33568617-F0E65360-404D-45FD-8711-8E9E0927C444Q33697846-9110D37D-0972-4735-A9DB-CE0684525E11Q33725032-2A37E904-2EEF-4BFC-A184-0234C1630A57Q34192954-AD0CFCB7-A234-46F9-9983-6E0EC0520E2EQ34273468-9077CF4C-D844-4CB2-BFC5-E6F06E4FAC12Q34279117-96F8DB47-8C32-4E00-921C-8AF8D4DB1884Q34364866-5C99D2AB-44E9-4E88-AD9B-469E0182A598Q34724535-69F7D8ED-CFC7-4B7F-A9FE-7C57FE8B1B86Q35055532-B7D2F40C-3861-4C93-83B5-1C04FEE9D5DEQ35536616-FDCDC8FE-D80D-47AA-8027-3B026C6A9F2AQ36765980-5DD629CB-1087-4603-BDD2-EDA2C8B8A129Q37042266-1A51EAD1-0601-42F5-90D2-118E7DB9E4F5Q37097729-CF002AB5-A995-455D-BA01-02D9C1DFE5F4Q37181742-81BF391E-E2A6-4347-8CA1-9B4DFE2B2900Q37299822-FA3507E0-523D-4C78-BAD1-45A6D65C74C5Q37976476-D4BA7C3F-3238-4B36-9000-CD6510A32DE5Q38003661-F7150AAE-DD86-4357-8898-9CB3E2FF3CF2Q38070209-B25BB460-AB57-4053-A34E-82C434F182D5Q38645834-C7A78541-52DE-4C3F-B530-9712F9ABCE79Q40724048-41B2FB10-1EAA-4361-AAA8-B28BB02CBD8BQ41779780-6BCB921D-9626-4F4E-820A-30542F86B680Q43545273-F19E88B2-41BE-4F30-AC68-F72088D2B8D7Q43562540-72FC65FE-BC55-4C67-AE0D-C1D554F1C418Q47697881-065F2DB1-CFDC-4A98-BC6E-3D2265C606D3Q51093869-226E3A7C-F820-420C-A751-D176AD65EA76Q51717811-CC67D8D2-EC4A-442D-9DF4-6695CF4A655E
P2860
Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@ast
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@en
type
label
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@ast
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@en
prefLabel
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@ast
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@en
P2093
P2860
P356
P1433
P1476
Increase in exhaled nitric oxi ...... ids. Asthma and Allergy Group.
@en
P2093
Campbell D
Kharitonov SA
Robinson DS
Stirling RG
P2860
P304
P356
10.1136/THX.53.12.1030
P407
P577
1998-12-01T00:00:00Z